Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
St. Petersburg、ロシア連邦、197376
- Research Institute of Influenza
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Legal male or female adult 18 through 49 years of age at the enrollment visit.
- Literate and willing to provide written informed consent.
- Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination.
- Capable and willing to complete diary cards and willing to return for all follow-up visits
- Willing to comply with the rules of the isolation unit (including willing and able to take oseltamivir influenza antiviral medication, should that be recommended by a study physician).
- For females, willing to take reliable birth control measures throughout the entire period of participation in the study.
Exclusion Criteria:
- Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.
- Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until four weeks after study completion.
- Practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment.
- Recent history of frequent nose bleeds (>5 within the past year).
- Clinically relevant abnormal paranasal anatomy.
- Recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose.
- Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.
- Other acute illness at the time of study enrollment.
- Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products during the period of subject participation in the study.
- Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, 0.5 mg per kg per day; topical steroids are allowed, exclusive of nasal.)
- Participation in any previous trial of any H5 or H7 containing influenza vaccine.
- History of asthma.
- Hypersensitivity after previous administration of any influenza vaccine.
- History of wheezing after past receipt of any live influenza vaccine.
- Other adverse event (AE) following immunization, at least possibly related to previous receipt of any influenza vaccine.
- Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.
- Seasonal (autumnal) hypersensitivity to the natural environment.
- Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. Subjects with physical examination findings or clinical laboratory screening results which would be graded 2 or higher on the AE severity grading scale (see Attachments) will be excluded from entry into the study and will be excluded from receipt of dose two of study vaccine or placebo.
- History of leukemia or any other blood or solid organ cancer.
- History of thrombocytopenic purpura or known bleeding disorder.
- History of seizures.
- Known or suspected immunosuppressive or immunodeficient condition of any kind, including HIV infection.
- Known chronic hepatitis B (HBV) or hepatitis C (HCV) infection.
- Known tuberculosis infection or evidence of previous tuberculosis exposure.
- History of chronic alcohol abuse and/or illegal drug use.
- Claustrophobia or sociophobia.
- Pregnancy or lactation. (A negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential.)
- Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:LAIV H5N2
Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
|
2 doses provided intranasally
他の名前:
|
プラセボコンパレーター:Placebo
two doses of placebo solution intranasal
|
2 doses of placebo provided intranasally
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Adverse Events by Severity
時間枠:6 days
|
Occurrence of participants with adverse events associated with intranasal administration, by worst grade of severity
|
6 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number/Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI)
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Defined as a four-fold or greater antibody rise in titer from pre-vaccination level. HAI = hemagglutination-inhibition, conducted using World Health Organization (WHO)-recommended protocols. |
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects With Serum Neutralizing Antibodies
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Defined as a four-fold or greater antibody rise in titer from pre-vaccination level. Measured by microneutralization assay in Madin-Darby canine kidney cells (MDCK). |
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin A (IgA)
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
IgA = immunoglobulin class A antibodies Determined using ELISA using whole purified H5N2
|
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin G (IgG)
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Determined using ELISA using whole purified H5N2.
|
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects With Seroconversion for Secretory IgA
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
IgA antibodies from the nasal mucosa detected in nasal wick specimens.
Determined using ELISA using whole purified H5N2
|
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects With Seroconversion for IgA in Saliva
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
IgA = Immunoglobulin Class A antibodies.
Determined using ELISA using whole purified H5N2.
|
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Vaccinated Participants Shedding Influenza Virus After First Dose
時間枠:6 days post-vaccination
|
Nasal swabs were collected and used for Reverse transcription polymerase chain reaction (rRTPCR) assays to detect shedding of influenza virus for days 1-6 of the study.
|
6 days post-vaccination
|
Number/Percentage of Vaccinated Participants Shedding Influenza Virus After Second Dose
時間枠:6 days post-vaccination
|
Nasal swabs were collected and used for Reverse transcription polymerase chain reaction (rRTPCR) assays to detect shedding of influenza virus for days 29-34 of the study (6 days after the second vaccination).
|
6 days post-vaccination
|
Geometric Mean Titers for Serum HAI Antibodies
時間枠:0 days, 28 days (Dose 1) and 56 days (Dose 2)
|
Geometric mean titers for serum hemagglutination inhibition antibodies
|
0 days, 28 days (Dose 1) and 56 days (Dose 2)
|
Geometric Mean Titers (GMT) for Serum Neutralizing Antibodies
時間枠:0 days, 28 days (Dose 1) and 56 days (Dose 2)
|
Geometric mean titers for serum neutralizing antibodies measured by microneutralization assay
|
0 days, 28 days (Dose 1) and 56 days (Dose 2)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Responses
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old embryonated chicken eggs (ECE) followed by incubation at 32◦C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells. An increase in the number of antigenic-specific T cells greater than 3 standard deviations over the mean placebo values was regarded as a positive T cell response. |
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Responses
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32◦C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells. An increase in the number of antigenic-specific T cells greater than 3 standard deviations over the mean placebo values was regarded as a positive T cell response. |
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Effector Memory T Cell Responses
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32◦C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells. An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response. |
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Central Memory T Cell Responses
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32◦C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells. An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response. |
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Effector Memory T Cell Responses
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32◦C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells. An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response. |
28 days (Dose 1) and 56 days (Dose 2)
|
Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Central Memory T Cell Responses
時間枠:28 days (Dose 1) and 56 days (Dose 2)
|
Nasal swabs from days 1, 2, 3, 5, and 7 after the first vaccination and on days 1 and 3, corresponding to days 29 and 31,respectively, after the second dose were tested for viral shedding by inoculation in 10- to 11-day-old ECE followed by incubation at 32◦C for 72 h. Influenza virus was detected by standard hemagglutination test with 1% chicken red blood cells. An increase in the number of antigenic-specific T cells greater than 3SD over the mean placebo values was regarded as a positive T cell response. |
28 days (Dose 1) and 56 days (Dose 2)
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Kiseleva I, Dubrovina I, Fedorova E, Larionova N, Isakova-Sivak I, Bazhenova E, Pisareva M, Kuznetsova V, Flores J, Rudenko L. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses. Vaccine. 2015 Dec 8;33(49):7008-14. doi: 10.1016/j.vaccine.2015.09.050. Epub 2015 Oct 2.
- Rudenko L, Kiseleva I, Stukova M, Erofeeva M, Naykhin A, Donina S, Larionova N, Pisareva M, Krivitskaya V, Flores J; Russian LAIV Trial Study Group. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. Vaccine. 2015 Sep 22;33(39):5110-7. doi: 10.1016/j.vaccine.2015.08.019. Epub 2015 Aug 19.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- LAIV-H5N2-01
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
LAIV H5N2の臨床試験
-
PATHInstitute of Experimental Medicine, Russia; Research Institute of Influenza, Russia完了
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS); Environmental Protection Agency...完了
-
Research Institute of Influenza, RussiaWorld Health Organization; Institute of Experimental Medicine, Russia; Joint Stock Company Microgen...わからない
-
PATHInstitute of Experimental Medicine, Russia; Ministry of Health, Russian Federation完了
-
Changchun BCHT Biotechnology Co.National Institutes for Food and Drug Control, China; Simoon Record Pharma Information Consulting... と他の協力者完了
-
Imperial College LondonPublic Health England完了
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID)終了しました
-
University of RochesterNational Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center完了
-
Liverpool University Hospitals NHS Foundation TrustLiverpool School of Tropical Medicine; Sponsor GmbH完了
-
University of Alabama at Birmingham募集